Vanda Pharmaceuticals Inc. (VNDA) Announces Quarterly Earnings Results
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10), Bloomberg Earnings reports. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm had revenue of $41.30 million for the quarter, compared to analyst estimates of $43.90 million. During the same period last year, the firm earned ($0.01) EPS. The business’s quarterly revenue was up 7.3% compared to the same quarter last year.
Vanda Pharmaceuticals (NASDAQ VNDA) opened at $14.95 on Wednesday. Vanda Pharmaceuticals has a 1 year low of $12.70 and a 1 year high of $18.99.
Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 target price on the stock in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $26.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, October 29th. BidaskClub lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. HC Wainwright set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Piper Jaffray Companies set a $23.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. Vanda Pharmaceuticals has an average rating of “Buy” and an average target price of $22.00.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.